The release of the first overactive bladder (OAB) guidelines was associated with an increase in OAB diagnoses, a decrease in anticholinergic medication use, and a rise in beta-3 agonist use, according ...

SunRISe-5 and MoonRISe-1 trials investigate TAR-200 and TAR-210 in non-muscle-invasive bladder cancer, focusing on disease-free survival and recurrence prevention. ARASTEP trial evaluates darolutamide ...

Video content above is prompted by the following: Evolution of BPH Treatment Outcomes Dr Christopher Kelly discusses the evolution of patient outcomes with different benign prostatic hyperplasia (BPH) ...

“Like any disease state, you want to make sure you have the right diagnosis; otherwise, you're not going to have a successful treatment plan," says Karyn S. Eilber, MD. The landscape of treatment for ...

The use of onabotulinumtoxinA (onabotA, Botox) for the treatment of overactive bladder comes with several important considerations. The use of onabotulinumtoxinA (onabotA, Botox) for the treatment of ...

Low baseline IsoPSA index correlates with reduced risk of clinically significant prostate cancer in patients with elevated PSA levels. Patients with low IsoPSA index showed lower rates of prostate ...

We preview several noteworthy P2 presentations in the urologic oncology space. The American Urological Association (AUA) will try its luck in Las Vegas, Nevada for its 2025 annual meeting. Taking ...

Matthew D. Galsky, MD, discusses how urologists should approach patient selection for perioperative durvalumab plus chemotherapy based on eligibility criteria for the NIAGARA trial. The FDA approved ...

The AUA Annual Meeting will cover bladder cancer, prostate cancer, sexual health, and BPH, featuring practice-changing sessions and clinical trials. Interviews with experts will discuss new guidelines ...

The website is meant to educate patients and their caregivers on several aspects of the kidney cancer journey. Receiving an initial diagnosis of renal cell carcinoma (RCC) is often an overwhelming ...

Testicular cancer cure rates have improved, but challenges in recurrence prediction and quality of life management persist. Emerging biomarkers, such as miR-371a-3p, show promise in improving ...

A panelist discusses how the ARCHES and ARANOTE trials differ in their fundamental design elements, with ARCHES evaluating enzalutamide plus androgen deprivation therapy (ADT) vs placebo plus ADT in ...